? TRANSLATIONAL THERAPEUTICS (TT) The Translational Therapeutics (TT) Program at The Ohio State University Comprehensive Cancer Center (OSUCCC), co-led by David Carbone, MD, PhD, Blake Peterson, PhD, and Elaine Mardis, PhD, unites an outstanding team of 79 basic, translational and/or clinical researchers from 18 departments within The Ohio State University (OSU) Colleges of Medicine, Pharmacy, and Veterinary Medicine and Nationwide Children?s Hospital (NCH). The goal of the TT program is to translate advances in solid tumor molecular biology and promising preclinical studies into innovative clinical trials to improve the state of the art in the diagnosis and treatment of solid tumors. Solid tumors are by far the major causes of cancer death in our catchment area (the state of Ohio), dominated by diseases of special interest in this program, including lung, breast, colorectal, head and neck, thyroid, and gynecologic cancers. As a result of existing expertise and collaborative scientific efforts, as well as focused recruitments across a spectrum of disciplines, the TT program exhibits strength in basic and translational research in lung cancer, gastrointestinal malignancies, breast cancer, sarcoma, and glioblastoma, as well as newly enhanced capabilities in drug development.
The Specific Aims of the TT program are to: 1) identify and therapeutically target alterations in solid tumor proliferation and survival signaling pathways; 2) identify tumor-host interactions and target them via small molecule and immunotherapeutic approaches; and 3) develop and improve upon approaches for determining prognosis, selecting appropriate therapies, and evaluating the response to treatment. During the current funding cycle, the TT Program successfully recruited 28 solid tumor clinicians, basic scientists, and physician-scientists. In addition, TT investigators produced 1130 peer-reviewed publications; 178 of these were published in high impact (?10) journals, 16% resulted from intra- programmatic collaborations, and 31% from inter-programmatic collaborations; 74% were multi-institutional; a total of 86% were collaborative publications. TT members collaborated on programmatic grant submissions and were awarded one NCI P01, two U01s, and two UG1s, as well as two T32 training grants. The TT Program has $9.2M in current annual direct costs from peer-reviewed grants, $6.6M (71%) of which is from the NCI. The TT Program is well-integrated with the clinical teams via participation in the multidisciplinary Disease Specific Research Groups (DSRG) and organizes Pan-Disease Investigator-Initiated Trial meetings to catalyze interactions between DSRGs. As such, there were 4,070 accruals to interventional clinical trials during the last funding cycle, of which 3,351 (82%) were therapeutic, including 1,144 (28%) investigator-initiated trials. Future directions focused on the OSUCCC research priorities and cancers relevant to our catchment area and growth in cellular and checkpoint inhibitor research (adult and pediatric), immunogenomics, tumor resistance and tumor heterogeneity and small molecule drug development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10089997
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Malpeli, Giorgio; Barbi, Stefano; Greco, Corinna et al. (2018) MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget 9:19961-19979
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Wang, Jin-Ting; Xie, Wen-Quan; Liu, Fa-Quan et al. (2018) NADH protect against radiation enteritis by enhancing autophagy and inhibiting inflammation through PI3K/AKT pathway. Am J Transl Res 10:1713-1721
Karpurapu, Manjula; Lee, Yong Gyu; Qian, Ziqing et al. (2018) Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis. Oncotarget 9:10606-10620
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Tasselli, Giorgia; Filippucci, Sara; Borsella, Elisabetta et al. (2018) Yeast lipids from cardoon stalks, stranded driftwood and olive tree pruning residues as possible extra sources of oils for producing biofuels and biochemicals. Biotechnol Biofuels 11:147
Moliva, J I; Hossfeld, A P; Canan, C H et al. (2018) Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8+ T-cell-dependent manner. Mucosal Immunol 11:968-978
Suarez-Kelly, Lorena P; Akagi, Keiko; Reeser, Julie W et al. (2018) Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. Cold Spring Harb Mol Case Stud 4:
Dalton, William S; Sullivan, Daniel; Ecsedy, Jeffrey et al. (2018) Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. Clin Pharmacol Ther 104:23-26

Showing the most recent 10 out of 2602 publications